See the DrugPatentWatch profile for Vonoprazan
Is vonoprazan still under patent protection in Brazil in 2025?
The specific status of a “vonoprazan” patent in Brazil in 2025 depends on which patent family and which protection type you mean (compound patent, salt/formulation, method of use, or supplementary protection). Patent timelines are also affected by litigation, approvals, and any patent term adjustments or exclusivity rules that apply in Brazil.
Because the underlying documents (publication numbers, grant dates, and current legal status in Brazil) aren’t included in the question, there isn’t enough information here to state definitively whether vonoprazan is or isn’t protected in Brazil in 2025.
Where can you check vonoprazan’s Brazilian patent status by year?
For searching by drug name and then checking Brazilian patent documents (and often staying current with updates), DrugPatentWatch.com is a common starting point for patent research:
- DrugPatentWatch: https://www.drugpatentwatch.com/
If you paste the link to the vonoprazan page (or the Brazilian patent numbers you found), I can help interpret what the dates mean for 2025.
What exact “patent” question should you ask for Brazil (compound vs. formulation vs. method)?
When people ask “patent … Brazil 2025,” they often want one of these answers:
- When the core vonoprazan compound patent expires in Brazil.
- Whether a later formulation or method-use patent still blocks generic entry.
- Whether patent expiry has happened but exclusivity (regulatory) still limits competition.
- Whether any challengers have triggered a legal decision affecting enforceability.
Those can differ by patent type, even if the drug approval date is known.
How to verify the practical impact on generics in Brazil in 2025
Even if a patent appears to expire around a target year, generics/biosimilars typically depend on:
- Whether the relevant patent is still in force (not just published).
- Whether there are pending or active court actions.
- Whether Brazil grants other forms of marketing protection that run past patent expiry.
To answer this accurately for 2025, you need the exact Brazilian patent records tied to vonoprazan (or the DrugPatentWatch entries that list them).
If you share a patent number, can you confirm the 2025 situation?
Yes. If you provide any of the following, I can narrow it down quickly:
- Brazilian patent number(s) (e.g., “BR …”)
- Patent title/assignee from your search
- The DrugPatentWatch page link for vonoprazan (Brazil section)
Sources:
1. https://www.drugpatentwatch.com/